FTP Pharmacoeconomics and personalized treatment

The course units of the Course in Pharmacoeconomics and personalized treatment provides a hands-on, multidisciplinary approach that covers the basic aspects of Precision and value-added Medicine:

• risk-benefit
• cost-effectiveness

An effective and safe prescription of medicines (appropriate prescription) is a pillar of personalized treatment. It deals with clinical and economic validation of pharmacogenetic tests as personalized treatment tool. Although costly, these tests help reduce treatment personalization times required by the trial-and-error approach, hospitalization and cost of emergency interventions. Even innovative/personalized treatment is costly, however they are usually more effective and have less side effects than standard care over the long term.

The faculty comprises pharmacologists, doctors, hospital and local pharmacists, pharmaeconomists, epidemiologists, healthcare economists who work in Universities, pharmaceutical companies, hospitals, AIFA. Professors are involved in the two main training activities of the Course: Clinical pharmacology and Pharmacoeconomics.

The Course in Pharmacoeconomics and personalized treatment improves the skills of all pharmacy professionals in assessing the risk-benefit and cost-effectiveness of pharmacological treatment.

The course is addressed to students in biomedical or economic sciences, pharmacy professionals in different fields, and staff managers in hospitals or healthcare units.

The contents of the Course may be interesting for supra-enterprise institutions (i.e. Regions), which may promote the implementation of innovative treatment resource management solutions.

The Course in Pharmacoeconomics and Personalized Treatment provides 60 hours of online teaching divided into an introduction and eight modules:

Introductory sessions

Course presentation; objectives and methodology; meeting with the participants

Module 1

Fundamentals and mechanisms of pharmacological interactions; tools for preventing therapy errors in the frail elderly; risks and costs of inappropriate polypharmacy in the elderly – the clinician’s perspective

Module 2

Gender medicine: clinical, pharmacological, epidemiological, and healthcare equity aspects.

Module 3

Genetic basis of personalized therapy; application of pharmacogenetics in optimizing the costs of managing toxicities; clinical-translational research experiences; implementation of pharmacogenetics in Italy; real-world studies.

Module 4

The generic drug – pharmacokinetic, regulatory, and pharmacoeconomic aspects.

Module 5
Pain therapy; value-based medicine and lean management; pharmaceutical pricing and access; precision medicine in oncology

Module 6
Clinical pharmacology of antimicrobials; pharmacokinetics of biotechnological drugs (siRNA and monoclonal antibodies); regulatory aspects of biosimilars

Module 7
Nutraceuticals – state of the art, critical issues, formulation perspectives; technological innovation; qualitative and regulatory aspects; clinical trials.

Module 8
Management and forecasting of resource consumption from a regional and national perspective: the budget impact methodology; tools for the sustainability of pharmaceutical expenditure; cost-effectiveness analysis of precision medicine.

The general ranking of merit for the academic year 2026/27 will be published on the Italian page of this Course according to the timing provided in the Call.